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Poster Session-II 123low-dose TBI with (n 5 45) or without (n 5 17) fludarabine, or cy-
clophosphamide plus fludarabine (n 5 12). T-reg (CD41FoxP31)
levels on days 40, 100, 180 and 365 were determined by flow cytom-
etry. Chimerism levels among total white blood cells, CD31 T-cells
andCD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels.
Results:Mean Treg (6 SD) levels in controls were 316 18 cells/
mL.Mean (6 SD) Treg levels on day 100 were 206 24 cells /mL (p\
0.01 in comparison to controls) in patients without grade II-IV acute
GVHD before day 100, and 27 6 21 cells/mL (NS) in patients with
an antecedent of grade II-IV acute GVHD. Mean 6 donor CD31
T-cells and Treg chimerism levels on day 100 were 75 6 29% and
81 6 18%, respectively (NS). Day 100 chimerism levels among
CD31 T-cells and Tregs were highly correlated (r 5 0.78, p \
0.01). The 1-year probability of grade II-III NIH chronic GVHD
in patients with day 100 Treg levels below or above median was
53% and 36%, respectively (P 5 0.13). SjTREC levels significantly
increased from day 100 to day 365 after HCT (p\ 0.01), demon-
strating thymic recovery. Finally, Treg and sjTREC levels correlated
on days 100 (r 5 0.48, p\ 0.01) and 365 (r 5 0.47, p\ 0.01) after
HCT.
Conclusions: Our data did not show thus far a significant corre-
lation between Treg levels and occurrence of chronic GVHD. The
association between Treg and TREC levels on days 100 and 365
might suggest a role for the thymus in regulating Tregs levels after
HCT, or that similar factors affect thymic function and Treg levels
after nonmyeloablative conditioning. Data including higher number
of patients will be presented.343
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Introduction: Long-term remissions have been observed follow-
ing allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for the treatment of chronic lymphocytic leukemia (CLL). Unfortu-
nately, many CLL patients are ineligible for transplant due to the
lack of an HLA-compatible donor. Umbilical cord blood (UCB)
HSCT permits transplantation of many individuals who are ineligi-
ble for allo-HSCTdue to its reduced requirement for stringentHLA
matching; however, disease relapse remains a significant complica-
tion. Further, unlike allo-HSCT, donor lymphocyte infusion
(DLI) cannot be employed as a post-transplant therapy. To address
this issue we are developing a strategy to generate CLL-specific
T-lymphocytes to be employed as a post-UCB-HSCT therapeutic
treatment.
Methods:CLL-specific antigen presenting cells (APC) were gen-
erated by the transduction of CLL cells with an adenoviral vector en-
coding CD154 (CD40L). Successful transduction and subsequent
CD40 ligation in CLL cells were verified by monitoring CD95 ex-
pression. CLL APCwere then used to prime partially HLAmatched
(typically 4/6) UCB lymphocytes in the presence of IL-12, IL-2,
IL-7, and IL-15. Expanded UCB lymphocytes were phenotyped by
flow cytometry, and CLL specificity was determined by ELISpot
and 51Cr lysis using non-CLL (CD19-/CD31) patient lymphocytes
as allo-antigen controls.
Results: Effector cell phenotype was predominantly (.80%)
CD41; however, skewing towardCD81 expansion could be achieved
by incubation in IL-12 during priming. Significant populations of ef-
fector memory (CD62L1CD1271) and central memory
(CD62L-CD1271) cells were observed following repeated stimula-
tions with CLL-APC. Significant expansion (.4 fold) of UCB lym-
phocyte populations was typically observed. In ELISpot assays,
CLL-APC primed UCB lymphocyte responders exhibited a signifi-
cant increase (p . 0.05) in IFN-g ELISpots when incubated with
CLL stimulators in comparison to non-CLL control stimulators.Cytolytic activity was demonstrated against unmodified CLL cells
by 51Cr release assays in which percent lysis of CLL targets was
30–50% at E:T ratios of 10:1 and 20:1. Lysis of autologous non-
CLL control targets was negligible.
Conclusions: Our results demonstrate that in vitro generation of
CLL-specific effectors from partially HLA-matched UCB lympho-
cytes is both feasible and practical. These preclinical results support
further exploration of this technique as a promising treatment mo-
dality in conjunction with UCB-HSCT.344
THE T CELL CYTOLYTIC MOLECULES FAS LIGAND AND TRAIL, THE TRAF-
FICKING MOLECULES CCR9, 7 INTEGRIN AND PSGL1, AND THE IMMUNE
MODULATING MOLECULES OX40 AND CEACAM1 ARE REQUIRED FOR
THYMIC GRAFT-VERSUS-HOST DISEASE
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Thymic graft-versus-host-disease (tGVHD) contributes to im-
paired T cell reconstitution after allogeneic bone marrow transplan-
tation, but its pathophysiology has not been well defined. We
assessed thymic output (RAG21 splenic recent thymic emigrants)
as well as the thymic cellularity (esp. CD41CD81 cells) and found
that these were inversely related to numbers of mature donor T cells
in the allograft. Bcl-2 expression in donor BM-derived thymocytes
was decreased in recipients with GVHD vs. those without GVHD,
which suggests that survival of thymocytes is decreased during
tGVHD. Consequently, tGVHD severity may be associated with
thymic function We studied the migration of alloreactive donor T
cells in vivo and found that donor T cells infiltrated the thymus
within the first week post-transplant. Upon adoptive transfer of
CFSE-labeled donor T cells we noted that thymus-infiltrating allor-
eactive donorT cells were fast-proliferating (CFSElo) and highly ac-
tivated (CD251CD441). We then analyzed T cell trafficking in
tGVHDwithmice deficient for certain traffickingmolecules, and as-
sessed tGVHD by loss of BM-derived CD41CD81 thymocytes.
We found that CCR9, b7 integrin, and PSGL1 were all partially re-
quired for tGVHD, while L-selectin and aE integrin may be dis-
pensable. Similarly, we examined the role of T cell cytolytic
pathways for tGVHD, and found that FasL and TRAIL were re-
quired for tGVHD, but that perforin andTNFwere dispensable. Fi-
nally, we assessed the role of various T cell regulatory molecules for
tGVHD, and found that Ceacam1 and OX40 were required, while
GITR was partially required and ICOS was dispensable. Host
non-hematopoietic thymic stroma may be an important target for
donor alloreactive T cells in GVH reaction models. We assessed
the expression of the death receptors Fas and DR5 in thymic stroma
fromnormal and irradiated (8.5Gy) BALB/cmice, and observed that
in particular, MHC class II-negative stroma (endothelial cells and fi-
broblasts), as well as a population of MHC class II-positive stroma
(epithelial cells) upregulated the expression of both Fas and DR5 af-
ter irradiation. Thymic epithelial cell numbers were relatively pre-
served after irradiation of mice deficient for TRAIL and FasL. In
conclusion, we found that TRAIL, TNF, CCR9, integrin b7,
PSGL1, Ceacam1 and OX40 on donor T cells as important for
tGVHD pathophysiology. These data suggest selective therapeutic
targets to attenuate tGVHD and improve post-transplant T-cell re-
constitution.345
ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE SCORING USING THE NIH
CONSENSUS CRITERIA
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Background: The NIH Oral cGVHD Activity Assessment In-
strument is intended to be simple to use and to provide a reproducible
objective measure of disease activity over time. The objective of this
studywas to assess inter- and intra-observer variability in the compo-
nent and composite scores in patients evaluated with oral cGVHD.
